In this study, we verified the efficacy of the EGFR-targeted drug gefitinib, which inhibits the TGF-β1-induced EMT in NSCLC cells, and cilengitide, a cyclic pentapeptide that enhances the inhibitory effect of gefitinib. Here, TGFB1 is linked to non-small cell lung carcinoma.